NeoStem obtains 2 EU patents for ischemia program

NeoStem (NBS) has received the first two European patents for its CD34 Cell program, in which the company is developing treatments for ischemia, when the supply of oxygenated blood in the body is restricted.

The IP is for "Compositions and Methods of Vascular Injury Repair."

The CD34 program now has 16 granted and allowed patents around the world. (PR)

Comments (1)
  • JT06
    , contributor
    Comments (4) | Send Message
    Anyone have a price target on NBS?
    20 May 2014, 02:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs